Ocular Therapeutix Inc (OCUL) has disclosed a new risk, in the Regulation category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ocular Therapeutix Inc. faces potential perception and governance risks as a portion of director and officer compensation is equity-based, leading to periodic insider sales or purchases under Rule 10b5-1 or other arrangements. While these trades are subject to insider trading policies and U.S. securities laws, ongoing sell-to-cover plans and diversification-driven transactions could be misinterpreted by investors as signals of reduced insider confidence or create volatility in the stock.
Overall, Wall Street has a Strong Buy consensus rating on OCUL stock based on 10 Buys.
To learn more about Ocular Therapeutix Inc’s risk factors, click here.